Navigation Links
Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
Date:9/12/2007

on, the company also plans to initiate quarterly conference calls with investors and analysts to discuss financial performance and to provide corporate updates, beginning with a call currently anticipated to be conducted in early October to discuss the company's fiscal 2007 performance.

About ONCONASE(R)

ONCONASE is a first-in-class product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit http://www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company
'/>"/>

SOURCE Alfacell Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. In Vitro and In Vivo Data Show Alfacells Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
3. Preclinical Data Show Alfacells Onconase Inhibits Tumor Growth of Non-Small Cell Lung Cancer, Breast Cancer Cells
4. Researchers Identify Intracellular Pathway of Alfacells Onconase
5. In vivo Study Results Demonstrating Potential of Alfacells Onconase for Treatment of Non-Small Cell Lung Cancer Published in Anticancer Research
6. Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacells Onconase
7. Alfacells Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
10. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
11. NCCN Updates Esophageal and Gastric Cancer Guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... -- Big Market Research presents a detailed analysis of ... , ( France , Germany , ... and Japan . Current scientific views on the ... 5-year test volume and sales forecasts by country for HAV NAT, ... Delta, HBc Ag, HBe Ag, and ALT/SGPT tests performed in the ...
(Date:5/5/2015)... China , May 5, 2015 Faced with ... rising public health awareness, China,s medical ... the markets with the largest demands have been ... Guangzhou and other first-tier cities. However, the entry ... short time makes these "high-end" markets in first-tier cities increasingly ...
(Date:5/5/2015)... RIDGEFIELD, Conn. , May 5, 2015 /PRNewswire/ ... abstracts from the company,s respiratory portfolio will be ... International Conference taking place May 15-20 in ... therapies for chronic obstructive pulmonary disease (COPD) and ... fibrosis (IPF) and COPD. Of the 29 accepted ...
Breaking Medicine Technology:2015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 22015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 3MEDITEXPO JIANGSU 2015 is to Help Medical Device Companies Explore Business Opportunities in Wider Markets 2MEDITEXPO JIANGSU 2015 is to Help Medical Device Companies Explore Business Opportunities in Wider Markets 3MEDITEXPO JIANGSU 2015 is to Help Medical Device Companies Explore Business Opportunities in Wider Markets 4Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 8Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 9Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 10Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 11Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 12Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 13Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 14
... Medical Systems Ltd. (Nasdaq: DHRM ) ("Dehaier" or ... and sale of medical devices and homecare medical products in ... the first quarter of fiscal 2011 ended March 31, 2011 ... in the United States. Company management will ...
... LOUIS, April 27, 2011 Stereotaxis, Inc. (Nasdaq: ... of its new Stereotaxis Epoch™  platform, a comprehensive ... recognized benefits of remote magnetic catheter control, the ... power of the Odyssey platform, enabling highly sophisticated ...
Cached Medicine Technology:Dehaier Medical to Report First Quarter 2011 Financial Results on May 4 2Stereotaxis Introduces New Electrophysiology Platform: Epoch™ 2Stereotaxis Introduces New Electrophysiology Platform: Epoch™ 3Stereotaxis Introduces New Electrophysiology Platform: Epoch™ 4
(Date:5/5/2015)... 05, 2015 On May, 5, 2015, My ... musician Irene Rose about alternatives for youngsters to do this ... you get the idea for starting a summer camp and ... an entertainment company called Once Upon a Party and I ... through songs and even scripture. We play games, sing, and ...
(Date:5/5/2015)... RF Technologies®, a leading provider of personal safety ... Solution with Voice Alarms. The ST750 will play a ... wait for assistance when it detects them starting to ... different melodies or tones or silent alerting, by integrating ... Alert®. , For 28 years, Sensatec Fall Management ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Major League ... with the belief that ultimate Frisbee™ is home to ... next sport that engages the world. Nike Ultimate Camps’ ... by creating opportunities for young athletes to learn about ... with MLU the perfect fit. , The Nike Ultimate ...
(Date:5/5/2015)... NovaSom, Inc., announced today that they ... with Ed Begley Jr., airing via Discovery Channel 3rd ... segment will focus on NovaSom, a leader in Obstructive ... their AccuSom® home sleep test, which is the only ... support and next-day test results and interpretation. , ...
(Date:5/5/2015)... Every year, news articles appear warning about the ... dry eye season is spring, also known as allergy season, ... United States. The only season offering a respite from seasonal ... of the Sharon Kleyne Hour™ Power of Water® radio show, ... May 11, 2015. Kleyne is the inventor of Nature’s Tears® ...
Breaking Medicine News(10 mins):Health News:My Positive Perspective Hosts Episode Informing People of a True Princess Summer Camp With Irene Rose 2Health News:RF Technologies® Releases Sensatec® ST750 Voice Alarm for Fall Management 2Health News:RF Technologies® Releases Sensatec® ST750 Voice Alarm for Fall Management 3Health News:US Sports Camps, Nike Ultimate Camps, and Major League Ultimate Host Youth Ultimate Summer Camps in Philidelphia 2Health News:Innovations with Ed Begley, Jr. to Explore NovaSom, Inc., in Upcoming Episode 2Health News:Nature’s Tears EyeMist tear film supplement soothes dry eye caused by spring pollen season, reports inventor Sharon Kleyne 2Health News:Nature’s Tears EyeMist tear film supplement soothes dry eye caused by spring pollen season, reports inventor Sharon Kleyne 3
... Robert I. Miller, a 25-year Siemens veteran, ... Industry Group within Siemens IT Solutions and Services, ... http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO )In this role, Miller will be ... business plan, including overall go-to-market activities, coordination with ...
... Palmetto GBA, a leading provider of technical and ... by the federal Centers for Medicare & Medicaid Services ... and perform related duties for South Carolina, North Carolina, ... process, CMS awarded Palmetto GBA a contract with a ...
... tomorrow,s (and even today,s) health problems may be found ... Consumer Electronics ShowLAS VEGAS, Jan. 9 /PRNewswire-USNewswire/ ... changing the way we shop, listen to music, and ... However, managing an illness or disability remains a frightening, ...
... strike fear in the hearts of men and those who ... shock of that diagnosis, suffered the grief and anger that ... of a lifetime. In his new book, "Life Begins at ... http://www.authorhouse.com ), he provides a valuable roadmap for those ...
... to Treat Diseases (HTDS) www.htdsmedical.com the company ... (Formerly ReNuYu Biochem) intends to recapitalize to 5 billion ... pending China Bio Chem merger. Consideration for Slavica is ... all doctors involved in Belgrade Serbia research. Key medical ...
... Jan. 8 New York City Mayor Michael R. ... and presented a proclamation to Ilchi Lee, president of ... Education, a revolutionary method of cognitive training to enhance ... is a globally-recognized thought leader regarding the power of ...
Cached Medicine News:Health News:Miller Joins Siemens IT Solutions and Services as V.P. of Healthcare Industry Group 2Health News:CMS Selects Palmetto GBA to Administer Medicare Program in Four States 2Health News:Meridian Makes CES Good For Your Health 2Health News:'Life Begins at 65: Words of a Cancer Survivor': New Book Offers Empowering Strategies for Rising Above Sickness and Setbacks 2Health News:'Life Begins at 65: Words of a Cancer Survivor': New Book Offers Empowering Strategies for Rising Above Sickness and Setbacks 3Health News:Hard To Treat Diseases (HTDS) Recapitalization 2Health News:NYC Mayor Michael R. Bloomberg Declares January 8th 'IBREA Brain Education Day' 2
... Tosoh Corporation launched the first generation HPLC ... HPLC/723Ghb brought a new level of automation ... forefront of diabetes testing in Japan. Now ... system, the G7 offers advanced automation; stable ...
... , Monoclonal antibody method for HbA1c ... study shows 99% agreement with the HPLC ... on a CV of 2.6%* means ... Standardization Program (NGSP) certified method, as recommended ...
... Maximize your laboratorys ... and enhanced automated workflow ... high-throughput automated workstation now ... and immunoassay with specimen ...
The sole coagulation analyzer in the world that uses a unique dry reagent card....
Medicine Products: